This extensively revised edition examines renal pathophysiology and the rationale for renal denervation for the management of hypertension, as well as possible long-term benefits and risks of this therapy. Renal denervation is a minimally invasive, endovascular catheter-based procedure that makes use of radiofrequency ablation to treat resistant hypertension, with studies showing a high degree of effectiveness. The devices involved in the continued evolution of this therapy are discussed and the book incorporates analyses of the development of the technique while evaluating its cost effectiveness and future applications.
Renal Denervation: Treatment and Device-Based Neuromodulation describes the technique in detail, its advances and its pitfalls. While it has been estimated that 50% of Western civilization has hypertension and approximately 20% of patients have resistant hypertension, hypertension remains the leading cause of cardiovascular morbidity and mortality thus strengthening arguments to consider a wider range of potential solutions to manage these patients.
Richard R. Heuser received his medical degree from the University of Wisconsin, School of Medicine in Madison, Wis., and completed his medicine internship and residency, as well as his cardiology fellowship, at The Johns Hopkins Hospital in Baltimore, Md. He currently serves as chief of cardiology at St. Luke’s Medical Center, and as the professor of medicine at the University of Arizona College of Medicine.
Markus P. Schlaich is a cardiologist at the Baker Heart and Diabetes Institute in the Hypertension and Kidney Disease Research Group.
Dagmara Hering is a visiting professor at the Medical University of Gdansk, Poland, and a Professorial Fellow at Baker IDI Heart and Diabetes Institute, Melbourne, Australia. She is a medical scientist and clinical specialist in internal medicine and hypertension. Her clinical research has been focused on the role of the sympathetic nervous system and its reflex mechanisms, arterial stiffness, and hemodynamics in the development of hypertension and its progression including cardiovascular and renal complications. She has substantially contributed to the understanding of the efficacy of novel device-based therapies for the management of hypertension, heart failure, and chronic kidney disease. She has received a total of 17 awards including those obtained from the Polish Society of Hypertension, European Society of Hypertension, International Society of Hypertension, High Blood Pressure Research Council of Australia, Polish Academy of Sciences, and Polish Academy of Arts and Sciences. She is a nucleus officer of the European Society of Hypertension Working Group on Hypertension and the Brain.
Dr Stefan Bertog is a cardiologist at the CardioVascular Center in Frankfurt, Germany. His clinical interests are coronary angiography and intervention, peripheral vascular disease, device-based treatment of resistant hypertension, and structural cardiac interventions including transcatheter aortic valve replacement and left atrial appendage and patent foramen ovale closure.
Dr Bertog received his medical degree from the Johannes Gutenberg University of Mainz, Germany, and a doctoral degree from the Goethe University, Frankfurt, Germany. After his internship in Frankfurt, Germany, he completed an internal medicine residency in Cleveland, OH, and cardiovascular disease as well as interventional cardiology fellowships at the University of Minnesota, Minneapolis, MN. He has been a staff cardiologist at the Minneapolis Veterans Affairs Medical Center since 2006 and at the CardioVascular Center in Frankfurt since 2013. He has been the co-director of TRENDS (conference on neurohumoral modulation) and invited to present research or lecture in Asia, Europe, and the US.
